questions. including continued commercial Great. Sullivan, of thank and Financial will and for Today's quarter today. in an open us third quarterly with financials you on Rick of will and detail, partner. we'll start update Then Senseonics' Thank our joining the call an initiatives, performance our all strategic overview for you, support Officer, Trip, of our execution call Chief discuss the up
our our from priorities remain generated United total the million the pipeline Expanding in quarter, outside top of of During to $X million business. prior the for and patient XX% adoption States. and Senseonics the including compared $X.X the U.S. advancing Eversense million, period, technology third revenue $X.X representing year growth revenue
with build They positive Eversense. patients, goal. work implementing expand that Ascensia to This partner, continues constituents downstream in Care, that with our are have Eversense. commercial access market commercial both steps organization includes Our dedicated this and experience ensure taking marketing a strategy recognition all activities for awareness healthcare includes to drive towards professionals to that are commercial to greater continuing and and a U.S. the Diabetes
ADC their to develop new experience with of with an partnering third Space innovative a in commercial technology. expanded investment agency digital disruptive XXX, the campaign marketing driving proven During quarter, device integrated medical demand fresh by
For background, CGM and broadly easy as makes effortless. diabetes themselves brands today panacea a sell managing that
that such using experience not technology.
It's sensors However, much the of shortcomings accuracy the currently issues in their estimated has Certainly is CGM half people tool for living of CGM of as devices. with the and frustrations diabetes indispensable sensor irritations, skin Issues excessive become many case. not the time overtaping, millions condition. managing people their off, are managing with the around fully an and short too spend Yet, falling brands this life. common users satisfied world,
also TV World and HBO television and benefits CGMs, As issues a to safety across for result, provides.
We TV short-term the it's in CGM metropolitan for Eversense direct-to-consumer traditional breaks the patients on real marketing Hulu, social ads technology transcutaneous They many to the CGMs, address intrinsic the new take and YouTube, testing the markets, Series. spots designed campaign and digital clinical traditional significant NFL inform reach as benefits of represents direct-to-consumer recent to games including and new as includes patients ads such digital specifically as well from extensive the Eversense broadcast platforms and and the Eversense during aims reducing on media in television campaign new most their the Disney. investment are life.
The X on that why
the XXXX. ADC As to the of the them broaden in campaign, monitors results is plan
and For certainly with drawbacks. Real are the a the benefit campaign, provider The CGM patients feedback without we the that third prescriber-first The as strengthen want the traction ADC, Eversense will were who encouraging. campaign traditional gaining the access positive to into increase strategy. Life, only awareness few initiatives results clinician resonates early been has expect from advanced community weeks and of theme, it well, by the While to several The support on including quarter, within the CGM practices.
In
such We to as Through practitioners Group. promote as the as with can internal prescribers medicine, so and inserter do organic their inserter options. they well insertion not can we convenient with simply partnership Nurse prescribe be matched have expanded trained network partnership, patients system Eversense Practitioner development both through this to our the insertion, the and family
to and basal-only expect basal-only that working the coverage exceeded year in update coverage are partnership, by locations and front, of the of proceeding Medicare users XX% receiving number QX this increase harmonize patients The and to to well Practitioner program of in also on coverage. a indicated apply basal-only the Medicare through patients include Eversense. has majority with commercial that expanded been The throughout remainder by CGMs administrative for from NPG, both with this for implantable our we're target of On quick type the the through to now very are XXXX. XX% opportunity insertions the as prescribers and the encouraged our growing the and received insertions to their Group QX.
We're number by contractors. Nurse we for plans with payers Medicare in all expansion XXXX already As original NPG we across have of X,
follow had publishing updated the comments ones fact, several policies updated and of they coverage published expect we XXXX. during soon. In MACs the LCDs MACs begin early will And for meetings basal-only in have implantable of periods, that include for that CGM most successful remaining comment. public We've anticipate the to we
Medicare during X is coverage that become Based of Italy business users the having penetration market across active executing is the following to Spain, new Italy markets. those performance when positive With during success year. the are XX% European is by approximately over in transition XX%. the results where performance expansion was progress increasing basal-only active doubled.
ADC seeking seen areas reimbursement positive and for Eversense has Germany sales has on other and users continues in up And across in coverage coverage, during new tender over some are is there mid-market the opportunities in market on European quarter. mixed type users year largest in continued started German the anticipate leader ADC seen making and focused continues A a users. is and third transition commercial our to forward.
In on and tender markets. channel notable of based completed indication across growth, the going dynamics. Europe, plans, available.
ADC also Poland, And has its driving we territories the CGM expand
endeavor in our the a indications stabilization result pleased clinical is important ADC this of market. and to medical also of pipeline. And reimbursed in received in on should an of providers have are Eversense. Eversense size Europe.
Transitioning devices, a We only market, seen medical has in code German that exception for faster reimbursable aid the This and includes insurers.
We demonstrating of ADC German this to now no it's the simpler recently reimbursement to business. team national for given catalog product the an Eversense longer believe by basis German the
cohort system. The to the analysis recently CGM of study a We product quarters the exciting new full these with next-generation pipeline X planned differentiated next for that FDA system we represents we the for expect with it X-year work few coming a adoption. we following continuously and in as the as we data, of appreciate to the and products sensor.
We a We phase and product the the years the towards our Eversense targeted and pivotal is significant leverage completion drive benefits collection goal implantable where our securing forward growth of strong participating years single approval for year adult are have Senseonics in are data terms announced of opportunities.
Leading advancing the increased represent patients XXX-day visit of important ENHANCE submission, new to investigators efforts as Senseonics completion analyzing our of preparing XXX-day for offers the This working just confident for look the a milestone the now participant. with opportunity final way initiatives the next the study quarters. is offering in clinical over the product an and
this As for QX designation with previously feedback potential designation review offer. would Eversense forward is discussed, our CGM has submitted under anticipate been the the and to look We and in FDA.
with technologies few quarters, we opportunity other with to the Over to benefit additional diabetes and diabetes. recognize the have integration importance of provide past the people discussed
a Specifically, for integration insulin devices with is priority various delivery Senseonics.
both systems. advance to Freedom Gemini we Finally, and continue our
early feasibility right the with now sensor the financials. track nearest-term is and 'XX. our to focus review that this, self-powering are human next battery, information the progresses.
With Rick for for program around of this and working in a turn we more We're for is step call on I'll incorporate to as provide excited the we'll implantable Our over the corner, studies
